The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Generic Oncology Drugs-Global Market Insights and Sales Trends 2024

Generic Oncology Drugs-Global Market Insights and Sales Trends 2024

Publishing Date : Nov, 2023

License Type :
 

Report Code : 1836337

No of Pages : 104

Ask Your Query

Synopsis

The global Generic Oncology Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Generic Oncology Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Generic Oncology Drugs market. Large Molecule Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Small Molecule Drugs segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Generic Oncology Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Generic Oncology Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Generic Oncology Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Generic Oncology Drugs sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Generic Oncology Drugs covered in this report include Pfizer, GlaxoSmithKline, Novartis, Merck, Celgene, Teva Pharmaceutical, Mylan, Aurobindo Pharma and Hikma Pharmaceuticals, etc.

The global Generic Oncology Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Merck
  • Celgene
  • Teva Pharmaceutical
  • Mylan
  • Aurobindo Pharma
  • Hikma Pharmaceuticals
  • Natco Pharma

Global Generic Oncology Drugs market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Generic Oncology Drugs market, Segment by Type:

  • Large Molecule Drugs
  • Small Molecule Drugs

Global Generic Oncology Drugs market, by Application

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Generic Oncology Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index

1 Market Overview of Generic Oncology Drugs
1.1 Generic Oncology Drugs Market Overview
1.1.1 Generic Oncology Drugs Product Scope
1.1.2 Generic Oncology Drugs Market Status and Outlook
1.2 Global Generic Oncology Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Generic Oncology Drugs Market Size by Region (2018-2029)
1.4 Global Generic Oncology Drugs Historic Market Size by Region (2018-2023)
1.5 Global Generic Oncology Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Generic Oncology Drugs Market Size (2018-2029)
1.6.1 North America Generic Oncology Drugs Market Size (2018-2029)
1.6.2 Europe Generic Oncology Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Generic Oncology Drugs Market Size (2018-2029)
1.6.4 Latin America Generic Oncology Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Generic Oncology Drugs Market Size (2018-2029)
2 Generic Oncology Drugs Market by Type
2.1 Introduction
2.1.1 Large Molecule Drugs
2.1.2 Small Molecule Drugs
2.2 Global Generic Oncology Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Generic Oncology Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Generic Oncology Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Generic Oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Generic Oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Generic Oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Generic Oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Generic Oncology Drugs Revenue Breakdown by Type (2018-2029)
3 Generic Oncology Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Generic Oncology Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Generic Oncology Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Generic Oncology Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Generic Oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Generic Oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Generic Oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Generic Oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Generic Oncology Drugs Revenue Breakdown by Application (2018-2029)
4 Generic Oncology Drugs Competition Analysis by Players
4.1 Global Generic Oncology Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Generic Oncology Drugs as of 2022)
4.3 Date of Key Players Enter into Generic Oncology Drugs Market
4.4 Global Top Players Generic Oncology Drugs Headquarters and Area Served
4.5 Key Players Generic Oncology Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Generic Oncology Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Generic Oncology Drugs Products, Services and Solutions
5.1.4 Pfizer Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Generic Oncology Drugs Products, Services and Solutions
5.2.4 GlaxoSmithKline Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Generic Oncology Drugs Products, Services and Solutions
5.3.4 Novartis Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Merck Recent Developments
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business
5.4.3 Merck Generic Oncology Drugs Products, Services and Solutions
5.4.4 Merck Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Merck Recent Developments
5.5 Celgene
5.5.1 Celgene Profile
5.5.2 Celgene Main Business
5.5.3 Celgene Generic Oncology Drugs Products, Services and Solutions
5.5.4 Celgene Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Celgene Recent Developments
5.6 Teva Pharmaceutical
5.6.1 Teva Pharmaceutical Profile
5.6.2 Teva Pharmaceutical Main Business
5.6.3 Teva Pharmaceutical Generic Oncology Drugs Products, Services and Solutions
5.6.4 Teva Pharmaceutical Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Teva Pharmaceutical Recent Developments
5.7 Mylan
5.7.1 Mylan Profile
5.7.2 Mylan Main Business
5.7.3 Mylan Generic Oncology Drugs Products, Services and Solutions
5.7.4 Mylan Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Mylan Recent Developments
5.8 Aurobindo Pharma
5.8.1 Aurobindo Pharma Profile
5.8.2 Aurobindo Pharma Main Business
5.8.3 Aurobindo Pharma Generic Oncology Drugs Products, Services and Solutions
5.8.4 Aurobindo Pharma Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Aurobindo Pharma Recent Developments
5.9 Hikma Pharmaceuticals
5.9.1 Hikma Pharmaceuticals Profile
5.9.2 Hikma Pharmaceuticals Main Business
5.9.3 Hikma Pharmaceuticals Generic Oncology Drugs Products, Services and Solutions
5.9.4 Hikma Pharmaceuticals Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Hikma Pharmaceuticals Recent Developments
5.10 Natco Pharma
5.10.1 Natco Pharma Profile
5.10.2 Natco Pharma Main Business
5.10.3 Natco Pharma Generic Oncology Drugs Products, Services and Solutions
5.10.4 Natco Pharma Generic Oncology Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Natco Pharma Recent Developments
6 North America
6.1 North America Generic Oncology Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Generic Oncology Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Generic Oncology Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Generic Oncology Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Generic Oncology Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Generic Oncology Drugs Market Dynamics
11.1 Generic Oncology Drugs Industry Trends
11.2 Generic Oncology Drugs Market Drivers
11.3 Generic Oncology Drugs Market Challenges
11.4 Generic Oncology Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock